60 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
for commercial operations in the U.S. designed to support the commercialization of APHEXDA. In addition, we completed the onboarding of customer-facing
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
constraints of the third parties;
impact on our reputation in the marketplace if manufacturers of our products, once commercialized, fail to meet customer … operations in the U.S. designed to support the commercialization of APHEXDA. In addition, we completed the onboarding of customer-facing personnel
F-3
BLRX
Bioline Rx Ltd
29 Dec 23
Shelf registration (foreign)
4:15pm
they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold debt securities in street name
424B5
1unwywtb8oqb19viafp
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
drc4a yb1jo
15 Sep 22
Current report (foreign)
8:39am
424B5
0w81 bovn5
3 Sep 21
Prospectus supplement for primary offering
4:29pm
424B5
9fa0t
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
wl38eaq5lhe fb
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
qlv92nh
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
aguw jemr7fcrdp0
25 Sep 20
Prospectus supplement for primary offering
4:30pm
424B5
4ewzpufys05duqy6j
3 Jun 20
Prospectus supplement for primary offering
8:33am
424B5
zxfn71 ge1wjxt5bibmt
28 May 20
Prospectus supplement for primary offering
12:00pm
6-K
EX-99
1ahnde9ks9f3d3
7 Feb 19
As Representative of the several Underwriters
12:00pm
424B5
9w18 1e0dtplj0uezt02
5 Feb 19
Prospectus supplement for primary offering
5:12pm